SVB Securities analyst David Risinger upgraded Vertex Pharmaceuticals to Outperform from Market Perform with a price target of $374, up from $265, arguing that the company’s earnings growth and durability are "underappreciated."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals expands collaboration with Arbor Biotechnologies
- Opco reveals three biotech stocks that will outperform in 2023
- Vertex Pharmaceuticals downgraded to Hold from Buy at Jefferies
- FDA clears Vertex IND application for VX-522 to treat CF
- Vertex Pharmaceuticals, Entrada Therapeutics enter EEV therapeutics pact